Clinical trials: Phase 1, open to volunteers
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
This phase I trial tests the safety, side effects and best dose of glofitamab given with alternating cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)/ rituximab, dexamethasone, cytarabine…
- Conditions
- Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma
- Trial name
- NCT07444710
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Female Participants
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of [14C]Navlimetostat (BMS-986504) in healthy female participants
- Trial name
- NCT07777133
- Testing
- Navlimetostat, [14C]Navlimetostat
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Sjogren's Syndrome, Sjögren
R-2487 in Patients With Sjogren's Syndrome (SjD)
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome.
- Conditions
- Sjogren's Syndrome, Sjögren, Sjögren Syndrome, Unspecified
- Trial name
- R-2487-SjD-01 (NCT06297213)
- Testing
- R-2487
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Rise Therapeutics LLC
Influenza
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
This is a Phase 1, randomized, controlled, dose-ranging clinical trial to assess the safety and immunogenicity of novel influenza A Group 1 and influenza A Group 2 mRNA chimeric hemagglutinin (HA) vaccine candidates given as…
- Trial name
- NCT07703514
- Testing
- cH15/3, cH4/3, cH5/1N1
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelodysplastic Syndromes
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Background: Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications in children and adults.
- Trial name
- NCT06303193
- Testing
- pacritinib
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- National Cancer Institute (NCI)
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Topical TOR-582 Treatment of Epistaxis in HHT
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life.
- Trial name
- NCT07667413
- Testing
- Topical sirolimus ointment
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Dermatitis Atopic
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, Phase Ib study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HSK60002 tablets in approximately 60…
- Trial name
- NCT07920809
- Testing
- HSK60002 tablets
- Volunteers
- 60 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell Lymphoma
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas.
- Trial name
- PlaTform (NCT07018752)
- Testing
- roginolisib, golcadomide, azacitidine
- Where
- 20 sites in France
- Volunteers
- 80 people
- Sponsor
- The Lymphoma Academic Research Organisation
Asthma, Mild Asthma
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1)…
- Trial name
- NCT06433921
- Testing
- Salbutamol HFA-152a, Salbutamol HFA-134a
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced…
- Trial name
- NCT05384626
- Testing
- Neladalkib (NVL-655), Midazolam, Repaglinide
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 840 people
- Sponsor
- Nuvalent Inc.
Healthy, Renal Impairment
A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)
The purpose of this study is to learn what happens to MK-6916 in a person's body when given to participants with moderate or severe kidney impairment compared to healthy participants.
- Trial name
- NCT07922174
- Testing
- MK-6916
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Healthy
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein).
- Trial name
- NCT07258836
- Testing
- LY4214835
- Where
- 6 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)
Background: Transcranial magnetic stimulation (TMS) uses magnetic pulses to affect brain activity. A type of TMS called theta burst stimulation (TBS) is approved to treat people with major depression.
- Trial name
- NCT06868914
- Testing
- TMS (MagVenture MagPro 100 with MagOption)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy…
- Trial name
- NCT05432804
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Selinexor
- Where
- 39 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint…
- Trial name
- TdVax (NCT05077137)
- Testing
- Tetanus Diptheria Vaccine, Polio Boost Immunization
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Alcohol Use Disorder
Environment and Alcohol: A Pilot Study
Background: Alcohol use disorder (AUD) is a chronic disease that causes more than 140,000 US deaths each year. AUD treatment often includes therapy and medication.
- Trial name
- NCT06860607
- Testing
- Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Metastatic Colorectal Cancer
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are…
- Trial name
- NCT04929223
- Testing
- Inavolisib, Bevacizumab, Cetuximab
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Ductal Adenocarcinoma (PDAC)
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.
- Trial name
- FALCON (NCT07829185)
- Testing
- modified FOLFIRINOX, Pentamidine 300 MG Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Oklahoma
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period…
- Conditions
- Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT07437963
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.